Project Grant R01HL179124
Award Date
6/4/25
Completion Date
4/30/29
Dollars Obligated
$777K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $165,672 to The Leland Stanford Junior University to investigate the role of cardiac troponin I (cTnI) in mitochondrial dysfunction and its impact on genetic cardiomyopathies. The research aims to 1) determine the effects of cTnI phosphorylation and truncation on mitochondrial function, and 2) evaluate the impact of pathogenic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research program with three independent projects related to genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to The Broad Institute, Inc. for a project titled "From Genetic Basis to Mechanisms for Heart Failure." The project aims to leverage high-throughput functional genomics approaches, including cell painting and perturbation sequencing, to investigate the roles of genetic risk factors associated with heart...
This $2,044,805 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research project to advance the understanding of genetic mutations in the cardiac myosin binding protein C (cMyBP-C) that can lead to hypertrophic cardiomyopathy. The project aims to develop a data-driven pipeline to predict the mechanisms and severity of cMyBP-C missense mutations, test these predictions using...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a deep mutational scan of the MYH7 gene in genome-edited human induced pluripotent stem cell-derived cardiomyocytes. The $2,507,438 award, effective August 5, 2024 through April 30, 2029, aims to generate a comprehensive variant effect map for MYH7 to help interpret the growing number of MYH7 variants of unknown significance...
This federal Project Grant award R01HL174049, in the amount of $777,277.00, was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding will support research to elucidate the impact of genetic regulation of regulatory T cell (Treg) CD39 expression on the resolution of cardiac inflammation following myocardial infarction. The project aims to determine how CD39 activity on Tregs impacts cardiac inflammation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy. The research aims to uncover the cellular and molecular mechanisms by which impaired protein folding results in cardiac dysfunction, with a focus on identifying a novel therapeutic target...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere structure and function, and link these mechanisms to the development of hypertrophic cardiomyopathy (HCM). The total funding amount is $730,764 over the project...